Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Apr 21:13:68.
doi: 10.1186/1471-230X-13-68.

Management of irritable bowel syndrome in primary care: the results of an exploratory randomised controlled trial of mebeverine, methylcellulose, placebo and a self-management website

Hazel Everitt, Rona Moss-Morris, Alice Sibelli, Laura Tapp, Nicholas Coleman, Lucy Yardley, Peter Smith, Paul Little
Randomized Controlled Trial

Management of irritable bowel syndrome in primary care: the results of an exploratory randomised controlled trial of mebeverine, methylcellulose, placebo and a self-management website

Hazel Everitt et al. BMC Gastroenterol. .

Abstract

Background: Many patients with IBS suffer on-going symptoms. The evidence base is poor for IBS drugs but they are widely prescribed and advised in Guidelines. Cognitive Behavioural Therapy (CBT) can be helpful, but availability is poor in the NHS. We developed a web-based CBT self-management programme (Regul8) in partnership with patients and trialled it and common IBS medications in an exploratory factorial RCT to test trial procedures and provide information for a larger trial.

Methods: Patients, 16 to 60 years, with IBS symptoms fulfilling Rome III criteria were recruited via GP practices and randomised to over-encapsulated mebeverine, methylcellulose or placebo for 6 weeks and to 1 of 3 website conditions: Regul8 with a nurse telephone session and email support, Regul8 with minimal email support, or no website.

Results: 135 patients recruited from 26 GP practices. Mean IBS SSS score 241.9 (sd 87.7), IBS-QOL 64 (sd 20) at baseline. 91% follow-up at 12 weeks. Mean IBS SSS decreased by 35 points from baseline to 12 weeks. There was no significant difference in IBS SSS or IBS-QOL score between medication or website groups at 12 weeks, or in medication groups at 6 weeks, or IBS-QOL in website groups at 6 weeks. However, IBS SSS at 6 weeks was lower in the No website group than the website groups (IBS SSS no website =162.8 (95% CI 137.4-188.3), website 197.0 (172.4 - 221.7), Website + telephone support 208.0 (183.1-233.0) p = 0.037).

Conclusions: This exploratory study demonstrates feasibility and high follow-up rates and provides information for a larger trial. Primary outcomes (IBS SS and IBS QOL) did not reach significance at 6 or 12 weeks, apart from IBS SSS being lower in the no-website group at 6 weeks - this disappeared by 12 weeks. Improved Enablement suggests patients with access to the Regul8 website felt better able to cope with their symptoms than the non-website group. Improved SGA score in the Regul8 groups may indicate some overall improvement not captured on other measures.

Trial registration: ClinicalTrials.gov Identifier (NCT number): NCT00934973.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CONSORT diagram.
Figure 2
Figure 2
IBS symptom severity score at baseline, six and twelve weeks by website group.
Figure 3
Figure 3
IBS symptom severity score at baseline, six and twelve weeks by medicine group.
See this image and copyright information in PMC

References

    1. British Society of Gastroenterology. Care of patients with gastrointestinal disorders in the United Kingdom: a strategy for the future. Gut. 2007;56:1–56. - PubMed
    1. Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut. 2001;48(2):272–282. doi: 10.1136/gut.48.2.272. - DOI - PMC - PubMed
    1. Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P. Guidelines for the management of Irritable Bowel Syndrome. Gut. 2007;56(12):1770–1798. doi: 10.1136/gut.2007.119446.8-5-2007. - DOI - PMC - PubMed
    1. Prior A, Whorwell PJ. Double blind study of ispaghula in irritable bowel syndrome. Gut. 1987;28(11):1510–1513. doi: 10.1136/gut.28.11.1510. - DOI - PMC - PubMed
    1. NICE. Irritable bowel syndrome in adults. NICE; 2008. http://guidance.nice.org.uk/CG61.

Publication types

Associated data

LinkOut - more resources